Propofol
- CAS No.
- 2078-54-8
- Chemical Name:
- Propofol
- Synonyms
- 2,6-DIISOPROPYLPHENOL;DIPRIVAN;Propofol USP;Anepol;Ivofol;PD18215;AMpofol;Aquafol;Recofol;Dipravan
- CBNumber:
- CB4101882
- Molecular Formula:
- C12H18O
- Molecular Weight:
- 178.27
- MOL File:
- 2078-54-8.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/8/14 18:30:21
| Melting point | 18 °C (lit.) |
|---|---|
| Boiling point | 256 °C/764 mmHg (lit.) |
| Density | 0.962 g/mL at 25 °C (lit.) |
| vapor pressure | 5.6 mm Hg ( 100 °C) |
| refractive index |
n |
| Flash point | >230 °F |
| storage temp. | 2-8°C |
| solubility | Very slightly soluble in water, miscible with hexane and with methanol |
| pka | pKa 11.10(H2O,t =20)(Approximate) |
| form | <18°C Solid,>18°C Liquid |
| color | Pale Yellow to Yellow |
| Odor | at 100.00?%. mild phenolic |
| Water Solubility | Very slightly soluble in water. |
| Merck | 14,7834 |
| BRN | 1866484 |
| InChIKey | OLBCVFGFOZPWHH-UHFFFAOYSA-N |
| LogP | 3.790 |
| CAS DataBase Reference | 2078-54-8(CAS DataBase Reference) |
| NIST Chemistry Reference | Phenol, 2,6-bis(1-methylethyl)-(2078-54-8) |
| EPA Substance Registry System | 2,6-Diisopropylphenol (2078-54-8) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P264-P270-P301+P312-P302+P352-P305+P351+P338 | |||||||||
| Hazard Codes | Xn,T,F | |||||||||
| Risk Statements | 22-36/37/38-20/21/22-39/23/24/25-23/24/25-11 | |||||||||
| Safety Statements | 26-36/37/39-37/39-36-45-36/37-16-7 | |||||||||
| RIDADR | 2810 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | SL0810000 | |||||||||
| TSCA | Yes | |||||||||
| HazardClass | 6.1(b) | |||||||||
| PackingGroup | III | |||||||||
| HS Code | 29089990 | |||||||||
| Toxicity | dog,LD50,intravenous,30mg/kg (30mg/kg),Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 38, Pg. 1117, 1996. | |||||||||
| NFPA 704 |
|
Propofol price More Price(7)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | PHR1663 | Propofol Pharmaceutical Secondary Standard; Certified Reference Material | 2078-54-8 | 1ML | ₹15934.4 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | D126608 | 2,6-Diisopropylphenol 97% | 2078-54-8 | 5G | ₹2662.95 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | P-076 | Propofol solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant? | 2078-54-8 | 1ML | ₹13326.6 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | D126608 | 2,6-Diisopropylphenol 97% | 2078-54-8 | 100G | ₹3041.83 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 56931 | 2,6-Diisopropylphenol analytical standard | 2078-54-8 | 1ML | ₹6365.1 | 2022-06-14 | Buy |
Propofol Chemical Properties,Uses,Production
Description
Propofol is an injectable, short-acting general anesthetic with a low incidence of side effects.
Chemical Properties
Light Yellow Liquid
Uses
Propofol is an anesthetic used in veterinary medicine.
World Health Organization (WHO)
Propofol, a short acting injectable anaesthetic, was introduced in 1987. In April 1992, the Norwegian Medicines Control Board reported that prolonged use of propofol had been associated with two fatalities in children characterized by metabolic acidosis, liver enlargement, and cerebral oedema. The UK Committee on the Safety of Medicines has received 5 reports of deaths occurring in children who had received propofol while in intensive care.
Biological Functions
Propofol (Diprivan) is rapidly acting, has a short recovery
time, and possesses antiemetic properties. A rapid
onset of anesthesia (50 seconds) is achieved, and if no
other drug is administered, recovery will take place in 4
to 8 minutes.The recovery is attributed to redistribution
of the drug and rapid metabolism to glucuronide and
sulfate conjugates by the liver and extrahepatic tissues,
such as intestine and kidney.
Rapid recovery and its antiemetic properties make
propofol anesthesia very popular as an induction agent
for outpatient anesthesia. Propofol can also be used to
supplement inhalational anesthesia in longer procedures.
Both continuous infusion of propofol for conscious
sedation and with opioids for the maintenance of
anesthesia for cardiac surgery are acceptable techniques.
General Description
Propofol is an injectable sedative–hypnotic used for the inductionand maintenance of anesthesia or sedation. Propofolis only slightly soluble in water with an octanol/water partitioncoefficient of 6,761:1; thus, it is formulated as an oil-inwateremulsion. The fat component of the emulsion consistsof soybean oil, glycerol, and egg lecithin. The pKa of thepropanol hydroxyl is 11 and the injectable emulsion has apH of 7 to 8.5. Formulations contain either disodium ethylenediaminetetraaceticacid (EDTA) (0.005%) or sodiummetabisulfite to retard the growth of microorganisms. EDTAis a metal chelator and patients on propofol containingEDTA for extended periods of time excrete more zinc andiron in their urine. The clinical consequence of this is notknown but the manufacturer recommends that a drug holidayor zinc supplementation be considered after 5 days of therapy.
Biological Activity
Intravenous general anesthetic and hypnotic with a mode of action which includes potentiation of GABA-mediated inhibitory synaptic transmission, direct activation of the GABA A receptor and inhibition of glutamate receptor mediated excitatory synaptic transmission. Also potentiates P2X 4 receptor-mediated currents in P2X 4 -HEK293 cells.
Pharmacology
Propofol is primarily a hypnotic drug with substantial cardiorespiratory depressant actions and with no ability to produce neuromuscular blockade. While propofol lacks analgesic properties, its use permits lower doses of opioids. Likewise, less propofol is required for adequate hypnosis when it is administered with opioids.Thus, it is said that propofol and opioids interact synergistically.
Clinical Use
Generic formulations of propofol may contain sodiummetabisulfite as the antimicrobial agent, and patients allergicto sulfites, especially asthmatic patients, should avoid thisformulation. Aseptic technique must be followed and unusedportions of the drug must be discarded according to the manufacturer’s instructions to prevent microbial contaminationand possible sepsis.
Side effects
The dose of propofol should be reduced in older patients;
however, it does have a relatively linear dose–
response characteristic, and patients generally can be safely titrated. The pain on injection, especially when
small veins are used, can be considerably reduced if lidocaine
20 mg is administered first.
Anesthesia induction with propofol causes a significant
reduction in blood pressure that is proportional to
the severity of cardiovascular disease or the volume status
of the patient, or both. However, even in healthy patients
a significant reduction in systolic and mean arterial
blood pressure occurs. The reduction in pressure
appears to be associated with vasodilation and myocardial
depression. Although propofol decreases systemic
vascular resistance, reflex tachycardia is not observed.
This is in contrast to the actions of thiopental.
The heart rate stabilization produced by propofol relative
to other agents is likely the result of either resetting
or inhibiting the baroreflex, thus reducing the tachycardic
response to hypotension.
Since propofol does not depress the hemodynamic
response to laryngoscopy and intubation, its use may
permit wide swings in blood pressure at the time of induction
of anesthesia. Propofol should be used with utmost
caution in patients with cardiac disease.
Safety Profile
Poison by intravenous and intraperitoneal routes. Experimental reproductive effects. Combustible when exposed to heat or flame; can react with oxidizing materials. To fight fire, use foam, CO2, dry chemical. When heated to decomposition it emits acrid smoke and fumes. See also PHENOL
Propofol Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| SKVen Technologies Pvt.Ltd. | +91-7032295152 +91-7032295152 | Hyderabad, India | 81 | 58 | Inquiry |
| Vanquest Pharma Pvt Ltd | +91-9920897640 +91-9920897640 | Mumbai, India | 36 | 58 | Inquiry |
| Harman Finochem Ltd | +91-2226528080 +91-2226528080 | Maharashtra, India | 37 | 58 | Inquiry |
| DK Pharmachem Pvt Ltd | +91-2242153111 +91-2242153111 | Maharashtra, India | 37 | 58 | Inquiry |
| Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
| PROTECH TELELINKS | +91-8571891912 +91-9855060837 | Himachal Pradesh, India | 62 | 58 | Inquiry |
| SI Group India Limited | +91-2356660401 +91-2356660401 | Maharashtra, India | 32 | 58 | Inquiry |
| ASolution Pharmaceuticals Pvt Ltd | +91-9028098511 +91-9028098510 | Maharashtra, India | 15 | 58 | Inquiry |
| Unimark Remedies Ltd | +91-2267304120 +91-2267304120 | Maharashtra, India | 48 | 58 | Inquiry |
| Flowchem Pharma Pvt Ltd | +91-9606036218 +91-9845055636 | Karnataka, India | 33 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| SKVen Technologies Pvt.Ltd. | 58 |
| Vanquest Pharma Pvt Ltd | 58 |
| Harman Finochem Ltd | 58 |
| DK Pharmachem Pvt Ltd | 58 |
| Ralington Pharma | 58 |
| PROTECH TELELINKS | 58 |
| SI Group India Limited | 58 |
| ASolution Pharmaceuticals Pvt Ltd | 58 |
| Unimark Remedies Ltd | 58 |
| Flowchem Pharma Pvt Ltd | 58 |
Related articles
- Application and Synthesis of Propofol
- Propofol is derivative of phenol. It is a short-acting intravenous anesthetic and it belongs to the national banned drugs. The....
- Jun 1，2022
- Pharmacology of Propofol
- Propofol, an alkylphenol, became available commercially in 1986. Propofol is extremely lipid soluble but almost insoluble in w....
- Feb 23，2022
2078-54-8(Propofol)Related Search:
1of4
chevron_right